45 results
S-3ASR
ZNTL
Zentalis Pharmaceuticals Inc
29 Feb 24
Automatic shelf registration
5:14pm
Discovery Engine, to advance our ongoing research on protein degraders of undisclosed targets. We believe our product candidates are differentiated from … as novel small molecule inhibitors designed to inhibit undisclosed targets; our plans to develop our product candidates in combination with other therapies
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
8 Jan 24
Regulation FD Disclosure
7:03am
through combining rigorously selected targets with innovative linker-payload platforms. We believe that the linker-payload technology that underlies … undisclosed targets.”
Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock
8-K
EX-99.2
1wngibfp
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
s6by2xao
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
m5odq99
9 Aug 23
Regulation FD Disclosure
4:15pm
424B5
srvs18g598 5bmr3a0
15 Jun 23
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.2
z1nxew4j02m1ch7
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.3
ps6x ysf8ujqbc2xkdav
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
PRE 14A
kcmcax
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.2
m8f2st4i6fkkz53d18h8
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.2
eup2vab
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am